Kidney Failure, Chronic
Recent clinical, regulatory, research and industry developments relating to this disease.
Epidemiology of haemodialysis outcomes.
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents.
Update on Diabetic Nephropathy: Core Curriculum 2018.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q2 2027.
Clinical MilestonesViewHide
- 2026-06-04Immune Reset to Allow Access to Hla-compatible Kidney Transplantation in Hyperimmunized PatientsResults expected Q2 2027
- 2026-05-04Empagliflozin in ESKD - A Feasibility StudyPrimary completion
- 2025-10-15Effect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis (MIA) Syndrome in Hemodialysis Patients: A Randomized Controlled StudyPrimary completion
- 2025-08-30A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal TransplantPrimary completion
- 2026-06-04ClinicalImmune Reset to Allow Access to Hla-compatible Kidney Transplantation in Hyperimmunized PatientsResults expected Q2 2027
- 2026-05-04ClinicalEmpagliflozin in ESKD - A Feasibility StudyPrimary completion
- 2025-11-10ClinicalGlucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease PatientsTerminated
- 2025-10-15ClinicalEffect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis (MIA) Syndrome in Hemodialysis Patients: A Randomized Controlled StudyPrimary completion
- 2025-08-30ClinicalA Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal TransplantPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 1… (2023)
Approval — Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) asso… (2022)
Approval — Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and… (2014)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cardiac Tamponade1
- Cardiovascular Diseases1
- Disease Progression1
- Gastrointestinal Microbiome1
- Kidney Failure, Chronic1
- Metabolome1
- Pericardial Effusion1
- Pericarditis1
Leading journals6
- European heart journal2
- American journal of kidney diseases : the official journal of the National Kidney Foundation1
- Gut1
- International journal of molecular sciences1
- Nature reviews. Nephrology1
- The New England journal of medicine1
Leading researchers8
- Adler Y1
- Agewall S1
- Alegria E1
- Badano L1
- Barón-Esquivias G1
- Bello AK1
- Bian W1
- Bogaert J1
Affiliations (unnormalised)6
- Aerospace Center Hospital1
- Beijing Advanced Innovation Center for Food Nutrition and Human Health1
- Beijing AnZhen Hospital1
- Beijing Laboratory of Food Quality and Safety1
- Centre for Kidney Disease Research1
- Cornell University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
The grounding supports chronic kidney disease as a condition with various causal factors, but it does not specify the causes of chronic kidney failure itself. It does identify diabetic kidney disease/diabetic nephropathy as a leading cause of end-stage kidney disease in many settings.
The disease reflects advanced, irreversible loss of kidney function with marked reduction in filtration capacity and proteinuria. The supplied review material links CKD progression to systemic inflammation and oxidative stress, which are associated with complications such as atherosclerosis, anemia, and mineral and bone disorders.
The grounding supports diabetes as an important risk factor through its role in diabetic kidney disease and diabetic nephropathy, which commonly progress to end-stage kidney disease. It also identifies elevated blood pressure and dyslipidaemias as modifiable cardiovascular risk factors in the broader literature, but does not directly establish them as risk factors for chronic kidney failure in the supplied material.
Patients generally require kidney replacement therapy, especially hemodialysis or kidney transplantation. In diabetic nephropathy, therapy is described as including cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin-angiotensin system.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.